Johnson & Johnson stock launches catheter, slightly lower pre-market
Published on 10/21/2026 at 08:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCompany news and listing
- Johnson & Johnson launched a next-generation coronary catheter in the United States on October 20, 2026.
- MarketBeat identified Johnson & Johnson’s home listing as NYSE: JNJ in its October 20, 2026 report.
- Johnson & Johnson stock trades pre-market at EUR 229.40 at 8:29 a.m. CEST at Lang & Schwarz on October 21, 2026, 0.80 percent below the Xetra close of October 20, 2026.
Johnson & Johnson launched a next-generation Shockwave coronary catheter in the United States on October 20, 2026, according to MarketBeat. Johnson & Johnson stock trades pre-market at EUR 229.40 at 8:29 a.m. CEST at Lang & Schwarz on October 21, 2026, minus 0.80 percent below the Xetra close of October 20, 2026 (EUR 231.25).
Catheter launch reported
The report said the Shockwave C2 Aero Fly coronary intravascular lithotripsy catheter was launched in the U.S. MarketBeat also described the device as part of Johnson & Johnson’s MedTech business and cited the company’s Innovative Medicine activities in its company overview, with the report dated October 20, 2026.
Pre-market indication
The indication is minus EUR 1.85 versus the Xetra closing level used for the comparison. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Johnson & Johnson stock.
The group and its market
Johnson & Johnson operates as a global healthcare company through its Innovative Medicine and MedTech segments, according to MarketBeat. The same October 20, 2026 report identified the company’s home listing as NYSE: JNJ. Market context: Market report S&P 500.
